株式会社カワチ薬品 2024年3月期通期業績予想の修正に関するお知らせ

This document announces the revision of the full-year earnings forecast for the fiscal year ending March 2024 by Kawachi Pharmaceutical Co., Ltd. The revision is based on recent business trends, including an increase in outdoor activities due to the transition of COVID-19 to Category 5, which has led to a recovery in sales of beauty-related products. Additionally, efforts to improve operational efficiency at logistics centers and reduce electricity usage contributed to lower selling, general, and administrative expenses. As a result, both operating and ordinary profits exceeded initial forecasts. The revised earnings forecast includes sales of 286,500 million yen, operating profit of 7,000 million yen, ordinary profit of 8,000 million yen, and net profit attributable to shareholders of 4,800 million yen.